title: Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.
abstract: Few studies have compared treatment patterns, healthcare resource utilization (HRU), and costs in patients with metastatic breast cancer (mBC) receiving HER2 directed therapy. This study evaluated these outcomes in patients receiving trastuzumab or lapatinib. Adult women with mBC, who were initiated on trastuzumab or lapatinib, on or after March 13, 2007, were selected from the US-based PharMetrics® Integrated Database (2000-2011). Patients were required to be continuously enrolled in their healthcare plan for ≥6 months prior to and ≥30 days following trastuzumab or lapatinib initiation. Trastuzumab or lapatinib discontinuation rates (defined as a gap ≥45 consecutive days) were compared using multivariate Cox proportional-hazards models. HRU and monthly healthcare cost differences were estimated using multivariate negative binomial regression models and generalized linear models, respectively. Among the 643 patients who met the inclusion criteria, 381 and 262 patients were included in the trastuzumab and lapatinib groups, respectively. The majority of the 262 patients receiving lapatinib previously received trastuzumab (N = 171 [65.3%]). After adjustment for potential confounders, when compared to trastuzumab patients, lapatinib patients had a higher rate of treatment discontinuation (hazard ratio [HR] = 1.57; P < 0.001), a higher rate of outpatient visits (not treatment administration related) (IRR = 1.19; P < 0.004), and a lower rate of medical visits associated with treatment administration (IRR = 0.34; P < 0.001). There were no significant differences between the two groups in total monthly healthcare costs ($11,920 vs. $11,898 for trastuzumab and lapatinib patients, respectively; P = 0.451). Findings from our study show that, irrespective of the treatment initiated at index date, disease management in patients with mBC is associated with similar and substantial healthcare costs. Any differences in specific components of healthcare costs were associated with differences in the mode of treatment administration. Approximately 50% of all costs were non-drug related, and future studies should focus on how these costs may be controlled, regardless of mode of treatment administration.
authors.affiliation: Analysis Group, Inc., 1000 rue de la Gauchetière Ouest, Bureau 1200, Montreal, QC H3B 4W5 Canada.
authors.forename: Annie
authors.initials: A
authors.lastname: Guérin
authors.affiliation: Genentech, Inc., South San Francisco, CA USA.
authors.forename: Deepa
authors.initials: D
authors.lastname: Lalla
authors.affiliation: Analysis Group, Inc., 1000 rue de la Gauchetière Ouest, Bureau 1200, Montreal, QC H3B 4W5 Canada.
authors.forename: Geneviève
authors.initials: G
authors.lastname: Gauthier
authors.affiliation: Analysis Group, Inc., 1000 rue de la Gauchetière Ouest, Bureau 1200, Montreal, QC H3B 4W5 Canada.
authors.forename: Amy
authors.initials: A
authors.lastname: Styles
authors.affiliation: Analysis Group, Inc., 1000 rue de la Gauchetière Ouest, Bureau 1200, Montreal, QC H3B 4W5 Canada.
authors.forename: Eric Q
authors.initials: EQ
authors.lastname: Wu
authors.affiliation: Genentech, Inc., South San Francisco, CA USA.
authors.forename: Anthony
authors.initials: A
authors.lastname: Masaquel
authors.affiliation: Genentech, Inc., South San Francisco, CA USA.
authors.forename: Melissa G
authors.initials: MG
authors.lastname: Brammer
keywords: Lapatinib; Metastatic breast cancer; Trastuzumab